ArticleGastro hep advances2026
Opportunistic Upper Endoscopy at the Time of Screening Colonoscopy: Feasibility, Acceptability, and Patient Perspectives.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05566899 (Primary Objective), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Primary Objective: The Primary Objective of the Study is to Evaluate the Acceptability and Feasibility of EGD-SC
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gastric cancer is highly lethal due to late stage at discovery in the United States, yet no routine screening strategy exists. Opportunistic upper endoscopy (esophagogastroduodenoscopy [EGD]) performed during screening colonoscopy (concomitant EGD and routine colonoscopy [EGD-SC]) may provide a practical approach to early detection. We evaluated the feasibility, acceptability, patient perspectives, and diagnostic yield of EGD-SC. Methods: In this single-center, open-label, single-arm prospective pilot study, adults aged 45 to 80 years scheduled for colonoscopy without prior EGD in the past 5 years were enrolled. Feasibility was assessed by enrollment, additional procedural time, and safety. Acceptability, patient perspectives, beliefs, motivators, barriers, and satisfaction were assessed using preprocedure and postprocedure surveys. Gastric biopsies were evaluated for precancerous gastric lesions. Results: Of individuals contacted, 51.6% expressed interest and 26.6% enrolled (n = 50; median age 56; 48% male; 60% high risk). Median added time was 17 minutes (range, 9-26), with no complications. All respondents rated EGD-SC as satisfactory (n = 40, 100%) and 90% (n = 36) as acceptable; most preferred the combined procedure (n = 39, 97.5%) and would recommend it to family or friends (n = 37, 92.5%). Knowledge gaps were common: nearly half lacked awareness of gastric cancer risk factors; although 72% (n = 31) viewed screening as beneficial, only 23.3% (n = 10) perceived gastric cancer as severe, and none considered themselves highly susceptible. Diagnostic yield included Conclusion: EGD-SC is feasible, safe, and highly acceptable, with strong patient endorsement and meaningful detection of gastric cancer precursor lesions. Together, these results support risk-stratified EGD-SC as a promising and pragmatic strategy for gastric cancer prevention and early detection in the United States. This trial was registered at www.clinicaltrials.gov as NCT05566899.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.